• Apr 02, 2025

3 Reasons to Avoid HAE and 1 Stock to Buy Instead

Haemonetics has gotten torched over the last six months - since October 2024, its stock price has dropped 20.1% to $63.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.

  • Apr 02, 2025

2 Reasons to Sell PRVA and 1 Stock to Buy Instead

Even during a down period for the markets, Privia Health has gone against the grain, climbing to $22.91. Its shares have yielded a 29.3% return over the last six months, beating the S&P 500 by 30.9%. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

  • Apr 02, 2025

3 Reasons to Sell WYNN and 1 Stock to Buy Instead

Over the past six months, Wynn Resorts’s shares (currently trading at $83.10) have posted a disappointing 18.6% loss while the S&P 500 was down 1.7%. This may have investors wondering how to approach the situation.

  • Apr 02, 2025

3 Reasons NXPI is Risky and 1 Stock to Buy Instead

The past six months haven’t been great for NXP Semiconductors. It just made a new 52-week low of $188.11, and shareholders have lost 20.1% of their capital. This may have investors wondering how to approach the situation.